0001567619-20-020621.txt : 20201203 0001567619-20-020621.hdr.sgml : 20201203 20201203200308 ACCESSION NUMBER: 0001567619-20-020621 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20201201 FILED AS OF DATE: 20201203 DATE AS OF CHANGE: 20201203 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: BLATT LAWRENCE CENTRAL INDEX KEY: 0001242110 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39617 FILM NUMBER: 201368281 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Aligos Therapeutics, Inc. CENTRAL INDEX KEY: 0001799448 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: ONE CORPORATE DR., 2ND FLOOR CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 BUSINESS PHONE: (800) 466-6059 MAIL ADDRESS: STREET 1: ONE CORPORATE DR., 2ND FLOOR CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 4 1 doc1.xml FORM 4 X0306 4 2020-12-01 0 0001799448 Aligos Therapeutics, Inc. ALGS 0001242110 BLATT LAWRENCE C/O ALIGOS THERAPEUTICS, INC. 1 CORPORATE DRIVE, 2ND FLOOR SOUTH SAN FRANCISCO CA 94080 0 1 0 0 Chief Executive Officer Stock Option (Right to Buy) 16.18 2020-12-01 4 A 0 450000 0.00 A 2030-12-01 Common Stock 450000 450000 D 1/48th of the total number of shares vest in forty-eight (48) successive and equal monthly installments measured from December 1, 2020 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date. /s/ Lucinda Y. Quan, as attorney-in fact for Lawrence M. Blatt 2020-12-03